


PHARMACEUTICAL 2020



Minerva Neurosciences Inc. Rank 272 of 362





PHARMACEUTICAL 2020



Minerva Neurosciences Inc. Rank 272 of 362

The relative strengths and weaknesses of Minerva Neurosciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Minerva Neurosciences Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 125% points. The greatest weakness of Minerva Neurosciences Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 203% points.

The company's Economic Capital Ratio, given in the ranking table, is -413%, being 110% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	47,137
Cost of Goods Sold	0
Intangible Assets	30,069
Liabilities, Current	6,629
Liabilities, Non-Current	41,287
Other Assets	277
Other Compr. Net Income	0
Other Expenses	-2,254
Other Liabilities	1,803
Other Net Income	1,427
Property and Equipment	16
Research and Development	58,124
Revenues	0
Selling, General and Administrative Expense	17,741

Output Variable	Value in 1000 USD
Assets	77,499
Liabilities	49,719
Expenses	73,611
Stockholders Equity	27,780
Net Income	-72,183
Comprehensive Net Income	-72,183
Economic Capital Ratio	-413%